<DOC>
	<DOCNO>NCT00851084</DOCNO>
	<brief_summary>The primary objective study estimate progression-free survival rate 12 month two arm study . Secondary objective include evaluation overall objective response rate treatment , progression-free survival , overall survival , safety documentation potential immunogenicity aflibercept . This study non-comparative randomize trial power comparison efficacy endpoint . Rather , aim trial get , endpoint , estimation efficacy safety aflibercept combine modified FOLFOX6 regimen . In type non-comparative randomize trial , control FOLFOLX6 arm intend act check similarity current patient historical control respect clinical outcome give FOLFOX6 treatment .</brief_summary>
	<brief_title>Study Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Histologically proven adenocarcinoma colon rectum Metastatic disease amenable potentially curative treatment Prior therapy metastatic cancer colon rectum Prior treatment angiogenesis inhibitors The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Angiogenesis</keyword>
	<keyword>Colon cancer</keyword>
	<keyword>Rectal cancer</keyword>
	<keyword>Oxaliplatin</keyword>
</DOC>